DEVELOPING OF A NEW TOOL FOR EVALUATION OF
THERAPEUTIC ADHERENCE IN COPD
ADINA TURCU-ȘTIOLICĂ 1#, MARIA BOGDAN 1#*, ADRIANA-ELENA TĂEREL 2#, ANAMARIA BOBOIA 3#, MIHAELA-SIMONA SUBȚIRELU 1#, LILIANA GEORGETA FOIA 4#, VLAD PĂDUREANU 5#
1University of Medicine and Pharmacy of Craiova, Faculty of Pharmacy, 2-4 Petru Rareș Street, 200349, Craiova, Romania
2“Carol Davila” University of Medicine and Pharmacy, Faculty of Pharmacy, 6 Traian Vuia Street, 020956, Bucharest,
Romania
3“Iuliu Hațieganu” University of Medicine and Pharmacy, Faculty of Pharmacy, 8 Victor Babeș Street, 400012, Cluj-Napoca,
Romania
4“Grigore T. Popa” University of Medicine and Pharmacy, Faculty of Dental Medicine, 16 Universității Street, 700115, Iași,
Romania
5University of Medicine and Pharmacy of Craiova, Faculty of Medicine, 2-4 Petru Rareș Street, 200349, Craiova, Romania
*corresponding author: bogdanfmaria81@yahoo.com
#All authors have equal contribution.
Download Full Article

Abstract:
Patients-reported outcomes can be used to measure health concepts that cover the full spectrum of human functioning. The
objective of this study was to develop and validate a tool that could be used in assessment the adherence patients with chronic
obstructive pulmonary disease (COPD). In the second part of the questionnaire we used EQ-5D-5L. COPD is characterized
by progressive limitation of the respiratory flow which is not totally reversible. Pharmacological therapy is the basis for
COPD treatment and includes inhaled bronchodilators such as β2 adrenergic agonists (e.g. olodaterol) and anticholinergic
agents (e.g. tiotropium). Being a new treatment on the reimbursement list in Romania, the treatment with a fixed dose
combination of olodaterol and tiotropium was one of the inclusion criteria of patients with COPD in this study. The tool has
good measurement properties and provides a valid and reliable measure of COPD-specific adherence.

Top